Posts by Zachariah DeFilipp, MD
-
Enasidenib Safe, Well Tolerated As Maintenance After Stem Cell Transplantation for IDH2-Mutated Myeloid Malignancies
Amir T. Fathi, MD, Yi-Bin Chen, MD, Zachariah DeFilipp, MD, Areej El-Jawahri, MD and colleagues found in a phase 1 trial that enasidenib 100 mg/day was safe and well tolerated as maintenance therapy for IDH2-mutated myeloid malignancies after hematopoietic cell transplantation and showed preliminary clinical activity.
-
Ivosidenib Shows Promise As Maintenance Therapy for AML After Bone Marrow Transplant
Amir T. Fathi, MD, Yi-Bin Chen, MD, Zachariah DeFilipp, MD, Areej El-Jawahri, MD and colleagues found in a phase 1 trial that ivosidenib was safe and well tolerated as maintenance therapy for acute myeloid leukemia following allogeneic hematopoietic cell transplantation, and two-year outcomes were promising.
Biography
Dr. DeFilipp received his medical degree from Tel Aviv University's Sackler School of Medicine in 2010. Following his internship and residency in internal medicine at the Western Pennsylvania Allegheny Health System in Pittsburgh, PA, he completed his fellowship in hematology and medical oncology at the Winship Cancer Institute of Emory University in Atlanta, GA. In 2016, Dr. DeFilipp joined the Blood and Marrow Transplant Program at the Mass General Cancer Center.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
